Maximum Safe Resection of Glioblastoma Multiforme
Menée sur 291 patients atteints d'une tumeur oligodendrogliale anaplasique avec codélétion 1p/19q, cette étude met en évidence une association entre le statut mutationnel du gène de l'isocitrate déshydrogénase et le bénéfice, en termes de survie, d'un traitement par procarbazine, lomustine ou vincristine
Glioblastomamultiforme(GBM) is the most frequent and deadliest form of primary brain tumor. In the United States alone, 12,000 new cases are diagnosed each year. Despite decades of refinement, the standard treatment, which consists of surgical resection followed by adjuvant chemotherapy and radiation, still results in a dismal mean survival time of only 14 months. Nonetheless, subsets of patients can be identified who have an improved natural history and response to treatment. For instance, age and preoperative performance status, the tumor’s radiographic characteristics, and the tumor’s genetic and epigenetic features have all been demonstrated to influence prognosis and predict response to treatment. The 5-year follow-up data from the original regimen of concomitant temozolomide, an alkylating agent, and focal radiation therapy for GBM, have shown that for patients who present with methylguanine methyltransferase promoter methylation, the overall survival is 13.8%, in comparison with 0% for patients without methylation who are treated with radiation therapy alone...
Journal of Clinical Oncology , éditorial en libre accès, 2014